Related Experiment Video
Updated: May 29, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients
Jeremy Kiffel1, Yael Rahimzada, Howard Trachtman
1Division of Nephrology, Department of Pediatrics, Cohen Children's Medical Center, New Hyde Park, 11040, USA.
Insights
Focal segmental glomerulosclerosis (FSGS) is a growing cause of kidney failure with no effective treatments for non-responders. Research highlights genetic factors and the urgent need for clinical trials for better FSGS therapies.
Area of Science:
- Nephrology
- Glomerular Diseases
- Kidney Health
Background:
- Focal segmental glomerulosclerosis (FSGS) is a leading cause of acquired glomerular disease and end-stage kidney disease, with increasing global incidence.
- Current treatment options are limited, particularly for patients unresponsive to corticosteroids, and recurrence after kidney transplantation affects 20-25% of recipients.
- FSGS can be primary or secondary to conditions like obesity, infections, and vesicoureteral reflux, with recent research implicating genetic mutations in podocyte proteins.
Purpose of the Study:
- To underscore the critical need for developing novel and effective therapeutic strategies for focal segmental glomerulosclerosis (FSGS).
- To emphasize the importance of investigating genetic factors contributing to FSGS.
- To advocate for the initiation of randomized clinical trials to address FSGS in both native and transplanted kidneys.
Main Methods:
- Review of current literature on FSGS etiology and treatment.
- Analysis of factors contributing to primary and secondary FSGS.
- Identification of knowledge gaps in FSGS management and research.
Main Results:
- Focal segmental glomerulosclerosis (FSGS) is a significant and increasing cause of kidney failure worldwide.
- Genetic mutations in podocyte proteins are increasingly recognized as a cause of FSGS.
- There is a lack of proven therapies for FSGS patients who do not respond to standard treatments.
Conclusions:
- There is an urgent requirement for randomized clinical trials to establish safe and effective therapies for focal segmental glomerulosclerosis (FSGS).
- Further research into the genetic underpinnings of FSGS is crucial for therapeutic development.
- Improved treatments are needed for FSGS affecting native and transplanted kidneys.
Abstract:
Focal segmental glomerulosclerosis (FSGS) is one of the most common forms of acquired glomerular disease leading to end-stage kidney disease. Its incidence is rising around the world. There is no proven therapy for those patients who do not respond to corticosteroids and it can recur in 20% to 25% of patients who receive a kidney transplant. The disease can be primary, or it can be secondary to various conditions including vesicoureteral reflux, obesity, medications, and infections. Recent advances have demonstrated the important role of genetic mutations in podocyte proteins as a cause of FSGS. There is an urgent need for randomized clinical trials to develop safe and effective therapy for FSGS that occurs in the native or transplanted kidney.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Nephrons
Nephrotic Syndrome I : Introduction
Chronic Kidney Disease II: Clinical Manifestations
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous capillaries...

